Medicamen Organics (NSE:MEDIORG) Research & Development: ₹0.00 Mil (TTM As of Mar. 2026)


NSE:MEDIORG Medicamen Organics Ltd NSE:MEDIORG
21 GF Score
Price ₹24.20
! 11 Warning Signs
View Full Analysis

What is Medicamen Organics Research & Development?

Medicamen Organics NSE:MEDIORG -2.81% 21 Research & Development is ₹0.00 Mil as of Mar. 2026. GuruFocus rates NSE:MEDIORG with a GF Score™ of 21/100. The stock has 11 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Medicamen Organics's Research & Development for the six months ended in Mar. 2026 was ₹0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.00 Mil.

Medicamen Organics  (NSE:MEDIORG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Medicamen Organics Research & Development Related Terms

Medicamen Organics Research & Development Historical Data

* Premium members only.

The historical data trend for Medicamen Organics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicamen Organics Research & Development Chart

Medicamen Organics Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Medicamen Organics Semi-Annual Data
Mar21 Mar22 Mar23 Sep23 Mar24 Mar25 Mar26
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
NSE:MEDIORG
21GF Score
Medicamen Organics Ltd NSE:MEDIORG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medicamen Organics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.00 Mil mean?
Medicamen Organics (NSE:MEDIORG) has a Research & Development of ₹0.00 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Medicamen Organics and its competitors.
Is Medicamen Organics' Research & Development too high?
Medicamen Organics' current Research & Development is ₹0.00 Mil. Overall, Medicamen Organics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Medicamen Organics' Research & Development compare to ZTS and UTHR?
Medicamen Organics' Research & Development of ₹0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Medicamen Organics and its competitors. Medicamen Organics's current Research & Development is ₹0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicamen Organics stock overvalued right now?
Medicamen Organics (NSE:MEDIORG) has a current Research & Development of ₹0.00 Mil. The current Research & Development is ₹0.00 Mil. Medicamen Organics' overall GF Score™ is 21/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Medicamen Organics (NSE:MEDIORG), the current Research & Development is ₹0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medicamen Organics Business Description

Address Ashok Vihar Phase II, 10, Community Center No. 2, New Delhi, IND, 110052
Medicamen Organics Ltd develops, manufactures, and distributes a wide range of pharmaceutical dosage forms, including Tablets, Capsules, Oral Liquids, Ointments, Gel, Syrups, Suspension and Dry powders. The company operates two WHO Good Manufacturing Practice certified facilities in India, producing products for both domestic and international clients. It provides contract manufacturing and loan license services to various pharmaceutical companies and exports to several countries across Africa, CIS, and South Asia. The principal source of revenue is through the manufacturing, export, and contract services focused on generic and branded pharmaceutical formulations.
21GF Score

Get the complete analysis for NSE:MEDIORG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹24.20
Price